Why Neurocrine Biosciences, Inc. (NBIX) stock moved
Neurocrine Biosciences, Inc. (NBIX) shares rose 1.2% to $173.00 as of July 21, 2026, a modest gain from the prior close of $170.88. BestStocks flagged the session as a major change for NBIX. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for NBIX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
NBIX climbed 1.2% to $173.00
Neurocrine Biosciences, Inc. (NBIX) moved +1.30% from $178.24 to $180.55 on 2026-07-09, reaching a new 30-day high. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Monitor for any earnings announcements, pipeline updates, or analyst commentary that could sustain or reverse the current uptrend.
What it means for Neurocrine Biosciences, Inc. investors
For Neurocrine Biosciences, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.2% session move; NBIX moved +0.42% from $177.49 to $178.24 on 2026-07-08. Weighing against that: New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $195.60, implying +13.1% upside from $173.00. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 9 days out, the next report is the most likely near-term test of the move.
NBIX price reaction
NBIX last traded at $173.00, up $2.12 (+1.24%) from the previous close of $170.88. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $161.44 and $180.55, and it currently sits about 60% of the way up that band.
Bullish and bearish analyst opinions on Neurocrine Biosciences, Inc. (NBIX)
The consensus analyst price target on Neurocrine Biosciences, Inc. (NBIX) is $195.60, 13.1% above the recent $173.00. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on NBIX line up.
The bullish case
- Wall Street's consensus price target of $195.60 implies +13.1% upside from $173.00.
- The Street's most bullish target is $230.00 (+32.9%).
- Positive 1.2% session move.
- NBIX moved +0.42% from $177.49 to $178.24 on 2026-07-08.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $160.00 (-7.5%).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for NBIX
Frequently asked questions about NBIX
Why did Neurocrine Biosciences, Inc. (NBIX) stock move?
NBIX rose 1.2% to $173.00. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did NBIX stock rise?
NBIX gained 1.24% ($2.12) versus the prior close of $170.88, last trading at $173.00 on 0.8× average volume.
When is Neurocrine Biosciences, Inc.'s next earnings date?
NBIX's next earnings report is estimated for 2026-07-30 — about 9 days away.
What is the analyst price target for NBIX?
The consensus analyst price target for NBIX is $195.60, about 13.1% above the current $173.00. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.
How BestStocks tracks NBIX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared NBIX-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for NBIX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.